Web of Science: 19 cites, Scopus: 18 cites, Google Scholar: cites,
Positron emission tomography response evaluation from a randomized phase III trial of weekly nab -paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas
Ramanathan, R. K. (Mayo Clinic (USA))
Goldstein, D. (Prince of Wales Hospital (Australia))
Korn, R. L. (Scottsdale Medical Imaging, Ltd (USA))
Arena, F. (NYU Langone Arena Oncology (USA))
Moore, M. (Provencial Health Services Authority. BC Cancer Agency (Canada))
Siena, S. (Università degli Studi di Millano. Niguarda Cancer Center (Italy))
Teixeira, L. (Hôpital Saint-Antoine (France))
Tabernero Caturla, Josep (Institut d'Oncologia de la Vall Hebron (VHIO))
Van Laethem, J.-L. (University Clinic of Brussels. Hôpital Erasme (Belgium))
Liu, H. (Biostatistics and Research and Design. Celgene Corporation (USA))
McGovern, D. (Biostatistics and Research and Design. Celgene Corporation (USA))
Lu, B. (Biostatistics and Research and Design. Celgene Corporation (USA))
Von Hoff, D. D. (Translational Genomics Research Institute and Honor Health (USA))
Universitat Autònoma de Barcelona

Data: 2016
Resum: In a phase III pancreatic cancer study, tumor response by positron emission tomography (PET) (exploratory end point) predicted treatment efficacy, including longer overall survival. nab -Paclitaxel/gemcitabine had a significantly higher rate of metabolic response versus gemcitabine. Overall, 5× more patients had a metabolic response by PET compared with RECIST. PET may be a more sensitive measure of response than radiographic modalities. In the phase III MPACT trial, nab -paclitaxel plus gemcitabine (nab -P + Gem) demonstrated superior efficacy versus Gem alone for patients with metastatic pancreatic cancer. We sought to examine the feasibility of positron emission tomography (PET) and to compare metabolic response rates and associated correlations with efficacy in the MPACT trial. Patients with previously untreated metastatic adenocarcinoma of the pancreas were randomized 1:1 to receive nab -P + Gem or Gem alone. Treatment continued until disease progression by RECIST or unacceptable toxicity. PET scans were carried out on the first 257 patients enrolled at PET-equipped centers (PET cohort). Most patients (252 of 257) had ≥2 PET-avid lesions, and median maximum standardized uptake values at baseline were 4. 6 and 4. 5 in the nab -P + Gem and Gem-alone arms, respectively. In a pooled treatment arm analysis, a metabolic response by PET (best response at any time during study) was associated with longer overall survival (OS) (median 11. 3 versus 6. 9 months; HR, 0. 56; P < 0. 001). Efficacy results within each treatment arm appeared better for patients with a metabolic response. The metabolic response rate (best response and week 8 response) was higher for nab -P + Gem (best response: 72% versus 53%, P = 0. 002; week 8: 67% versus 51%; P = 0. 014). Efficacy in the PET cohort was greater for nab -P + Gem versus Gem alone, including for OS (median 10. 5 versus 8. 4 months; hazard ratio [HR], 0. 71; P = 0. 009) and ORR by RECIST (31% versus 11%; P < 0. 001). Pancreatic lesions were PET avid at baseline, and the rate of metabolic response was significantly higher for nab -P + Gem versus Gem alone at week 8 and for best response during study. Having a metabolic response was associated with longer survival, and more patients experienced a metabolic response than a RECIST-defined response. NCT00844649.
Drets: Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. Creative Commons
Llengua: Anglès.
Document: article ; recerca ; publishedVersion
Matèria: Pancreatic cancer ; Positron emission tomography ; Nab -paclitaxel ; Gemcitabine ; Metabolic response
Publicat a: Annals of Oncology, Vol. 27, Issue 4 (April 2016) , p. 648-653, ISSN 1569-8041

PMID: 26802153
DOI: 10.1093/annonc/mdw020


6 p, 180.0 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats

 Registre creat el 2018-02-07, darrera modificació el 2019-06-14



   Favorit i Compartir